Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MGd · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| WBRT | EXPERIMENTAL | 3 Gy of WBRT daily for a total of 10 days |
| MGd | EXPERIMENTAL | IV does of 5.0 mg/kg MGd plus WBRT |
| Name | Type | Description |
|---|---|---|
| WBRT | RADIATION | 3 GY of WBRT daily for a total of 10 days |
| MGd | DRUG | 5.0 mg /kg MGd plus WBRT |
DISEASE CHARACTERISTICS: Histologically proven solid tumor with parenchymal brain metastasis Solitary metastasis eligible only if refused surgery or surgical resection deemed inappropriate No leptomeningeal metastases or subarachnoid spread of tumor No small cell lung cancer, germ cell tumors, lymph...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
MGd is an investigational small molecule being studied for the treatment of metastatic cancer, specifically in patients with brain metastases. It is being evaluated in combination with radiation therapy. The drug is currently in Phase 3 clinical development.
MGd is a small molecule that acts as a radiation sensitizer. It is designed to enhance the effects of radiation therapy on cancer cells, potentially improving the effectiveness of treatment for metastatic cancer, particularly brain metastases.
MGd is being developed by AbbVie Inc., a biopharmaceutical company. AbbVie is listed on the stock exchange under the ticker symbol ABBV.
MGd is in Phase 3 clinical development. It has completed one Phase 3 trial, which was a randomized, controlled study. The drug is still investigational and has not been approved by regulatory authorities.
MGd has been studied in one completed Phase 3 clinical trial with the identifier NCT00003563. This trial evaluated radiation therapy plus gadolinium texaphyrin in treating patients with brain metastases. The trial enrolled 430 participants and was conducted in the United States and Canada.